Citi Downgrades Summit Therapeutics plc (SMMT) to Neutral, 'Valuation Looking Fair for Now'
Tweet Send to a Friend
Citi analyst Yigal Nochomovitz downgraded Summit Therapeutics plc (NASDAQ: SMMT) from Buy to Neutral with a price target of $23.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
